FGFR as potential target in the treatment of squamous non small cell lung cancer

Highlights • Squamous lung cancers have been regarded as tumors without targetable molecular alterations. • FGF/FGFR pathway deregulation is increasingly recognized across different tumors. • FGF/FGFR pathway is one of the most promising druggable target in squamous lung cancers. • FGFR amplificatio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2015-06, Vol.41 (6), p.527-539
Hauptverfasser:	Tiseo, Marcello, Gelsomino, Francesco, Alfieri, Roberta, Cavazzoni, Andrea, Bozzetti, Cecilia, De Giorgi, Anna Maria, Petronini, Pier Giorgio, Ardizzoni, Andrea
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Squamous Cell - drug therapy FGF FGFR Gene Amplification Gene Fusion Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Mutation NSCLC Protein Kinase Inhibitors - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - chemistry Receptor, Epidermal Growth Factor - genetics Receptor, Epidermal Growth Factor - physiology Signal Transduction Squamous cell carcinoma TKI
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Squamous lung cancers have been regarded as tumors without targetable molecular alterations. • FGF/FGFR pathway deregulation is increasingly recognized across different tumors. • FGF/FGFR pathway is one of the most promising druggable target in squamous lung cancers. • FGFR amplifications, mutations, translocations are the most frequent mechanisms of activation. • mAbs, ligand traps, TKIs directed versus FGF/FGFR are in development in lung tumor.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2015.04.011